Industry practitioners highlighted by PHCNA emphasize that real-time metabolic monitoring is moving from pilot to production in cell and gene therapy (CGT) workflows. Tia Harmon noted technologies that continuously track metabolites and cell health metrics enable earlier interventions, reduce batch failures, and tighten process control across complex upstream and downstream steps. Adoption of inline sensors and analytics aims to shorten cycle time for release testing and improve comparability between runs. For CGT manufacturers, the approach addresses yield variability and regulatory expectations for process understanding in advanced therapies.